Population-based analysis of the prevalence of BRAF mutation in patients diagnosed with cutaneous melanoma and its significance as a prognostic factor

被引：0
作者：
Jordi Rubió-Casadevall
Anna Carbó-Bagué
Montserrat Puigdemont
Gemma Osca-Gelis
Gloria Oliveras
Neus Vilar-Coromina
Berta Ferrer-Fabrega
Antoni Urban
Montserrat Llobet-Roma
Ferran Martín-Romero
Ferran Perez-Bueno
Rafael Marcos-Gragera
机构：
[1] Hospital Josep Trueta,Medical Oncology Department, Catalan Institute of Oncology
[2] Biomedical Research Institute of Girona (IDIBGI),Genetic Descriptive, Genetic and Prevention Epidemiology Group
[3] University of Girona (UdG),School of Medicine
[4] Catalan Institute of Oncology,Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan Department of Health Government of Catalonia
[5] University of Girona (UdG),School of Nursery
[6] Catalan Institute of Oncology and Catalan Institute of Health,Tumour Registry of University Hospital Josep Trueta
[7] Catalan Institute of Health,Pathology Department Hospital Josep Trueta
[8] Catalan Institute of Health,Dermatology Department, Hospital Josep Trueta
[9] Girona Clinic,Pathology Department
[10] Hospital Sant Jaume de Calella,Pathology Department, Corporació de Salut del Maresme La Selva
[11] Palamos Hospital,Pathology Department, Serveis de Salut Integrats Baix Empordà
[12] Figueres Hospital,Pathology Department, Fundació Salut Emporda
来源：
European Journal of Dermatology | 2021年 / 31卷
关键词：
melanoma; mutation; survival; prognostic factor; cancer registry; population-based study; epidemiology;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：616 / 622
页数：6
相关论文
共 77 条
[1]  
Curtin JA(2005)Distinct sets of genetic alterations in melanoma N Engl J Med 353 2135-47
[2]  
Fridlyand J(2010)Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 809-19
[3]  
Kageshita T(2015)Improved overall survival in melanomawith combined dabrafenib and trametinib N Engl J Med 372 30-9
[4]  
Flaherty KT(2011)Prognostic and clinico-pathologic associations of oncogenic BRAF in metastatic melanoma J Clin Oncol 29 123946-9
[5]  
Puzanov I(2012)BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma J Clin Oncol 30 2522-93
[6]  
Kim KB(2016)The molecular profile of metastatic melanoma in Australia Pathology 48 188-14
[7]  
Robert C(2015)BRAF V600 mutations and pathological features in Japanese melanoma patients Mel Res 25 9-100
[8]  
Karaszewska B C(2012)Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort Eur J Cancer 48 94-82
[9]  
Schachter J(2015)The role of BRAF mutations in primary melanoma growth rate and survival Br J Dermatol 173 76-95
[10]  
Long GV(2018)Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma Radiol Oncol 52 289-68
12345678